BiotechTube

ERY974

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Solid Tumors

Conditions

Solid Tumors

Trial Timeline

Aug 1, 2016 → Aug 1, 2019

NCT ID
NCT02748837

About ERY974

ERY974 is a phase 1 stage product being developed by Chugai Pharmaceutical for Solid Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT02748837. Target conditions include Solid Tumors.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT02748837Phase 1Completed

Competing Products

20 competing products in Solid Tumors

See all competitors
ProductCompanyStageHype Score
E7050EisaiPhase 1
33
AFM24 + Atezolizumab 840 MG in 14 ML InjectionAffimedPhase 1/2
33
EXS21546BiotrialPhase 1/2
33
SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent)Syros PharmaceuticalsPhase 1
25
BBP-398 + sotorasibBridgeBio PharmaPhase 1
30
BBP-398 (Formerly known as IACS-15509)BridgeBio PharmaPhase 1
30
SON-1010Sonnet BioTherapeuticsPhase 1
28
SON-1010Sonnet BioTherapeuticsPhase 1/2
36
RC220 + Doxorubicin (Adriamycin)Race OncologyPhase 1
25
BT1718Bicycle TherapeuticsPhase 1/2
33
NL-201 + Pembrolizumab Injection [Keytruda]NeurogenePhase 1
25
ZN-c3 + Carboplatin + Pegylated liposomal doxorubicin + Paclitaxel + Gemcitabine + BevacizumabZentalis PharmaceuticalsPhase 1
25
AzenosertibZentalis PharmaceuticalsPhase 1
25
IMC-18F1Eli LillyPhase 1
33
OKI-179OnKure TherapeuticsPhase 1
25
LY3499446 + Abemaciclib + Cetuximab + Erlotinib + DocetaxelEli LillyPhase 1/2
41
ACR-2316Acrivon TherapeuticsPhase 1
25
agenT-797 + Approved ICIsMiNK TherapeuticsPhase 1
25
LY3300054 + Ramucirumab + Abemaciclib + Merestinib + LY3321367Eli LillyPhase 1
33
BBP-398LianBioPhase 1
25

Other Products from Chugai Pharmaceutical

Satralizumab 120 mgApproved
85
Pegasys® + Pegasys®Approved
85
ED-71 + Alfacalcidol + ED-71 placebo + Alfacalcidol placeboPhase 3
77
R744 + Epoetin betaPhase 3
77
EmicizumabPhase 3
77